Please Login to share this post.
Share This Post
To:
(Separate emails by commas)
Message:
(Message is optional)
Description:
If you are an Investor, or know of an Investor desiring a unique and immediate investment opportunity geared toward the technological future of medicine, would you please take a few minutes and read over the following. I sincerely believe you may become quite interested in the potentially high ROI of this offering and of the potentials and possibilities presented by a ground floor investment in the future of therapeutic medical science technology.
Investment Request:
Our company a Florida based Medical Device Research and Development Company currently holding one (1) U.S. and twenty-three (23) Foreign Patents on its Technology and the usage of its applied Therapeutic wavelength, is seeking investment(s) to facilitate finalization of the FDA Clearance to Market process, for completion of Phase IV product development and manufacturing, and to aggressively bring its Immunogenic Technology and its unique Therapeutic Medical Modality, the Ig2000, to market.
Raising $500K Bridge and $2.5M 2nd-3rd year - PPM - Terms Negotiable.
Minimum funding investment threshold $25,000.
A Substantial Equity Position or Partnership is being offered for full-raise investment.
The Ig2000 is a Novel and Breakthrough Therapeutic Medical Modality incorporating a Technology that has world-wide market applications in both Human and Veterinary Medicine. The Modality/Device is Veterinarian proven with over 250,000 treatments having been successfully applied in Vet clinics over the past 10 years of research and limited sales. Treatments with the Device have shown consistent and positive resolutions to injuries, ailments and disease displaying an 80%+ success rate in therapeutic application with no negative side effects having been reported. Both Clinical and anecdotal treatments on human subjects have displayed the same remarkable results.
The Device is currently FDA Compliant as a Veterinary Medical Modality, Phase III completed for human medicine application, and less than 1 year away from obtaining its FDA Clearance to Market for Human Medical usage.
Company is Veterinary and Human Medicine device design, engineering, and prototype ready/completed.
Upon adequate Funding the Veterinary Device will immediately be manufactured and aggressively marketed throughout the Veterinary Medical field, and, after receiving its FDA Clearance to Market for Human Medicine usage, the Modality will be introduced into the Human Medical marketplace within less than one year. The Modality is currently being sold in the Veterinary Market in limited numbers where it has already proven its efficacy, marketability and profitability.
An existing agreement with a Major Medical Device Manufacturer is currently in place so that manufacturing of the newly designed and engineered Veterinary and Human Medical “Ig” Devices may begin as soon as the requested funding is achieved.
The Ig2000 is a “one of a kind” Medical Modality. It is a Disruptive Technology and a Technological Breakthrough in the field of Immune Modulation Therapy (IMT). Based on Quantum Physics, and Laser and Light Science, the Technology has the unique ability to non-invasively stimulate and up-modulate the Immune System and the Immune Response (in animal or human subjects) through the photo-manipulation of the molecules involved in the generation and production of the cellular communicator, nitric oxide.
This is not your father's Oldsmobile.
This is a serious Phase IV investment level opportunity. The company has already expended over $4M and 10+ years of hard work and sweat equity in bringing itself and the Technology to where it is today. The company is currently poised for increased manufacturing, sales growth, licensing, partnership and/or a buy out. We are seeking immediate Bridge Funding and mid-late stage developmental growth capital investiture, not "second" or "third round only" investment, please consider this before contacting.
The Company is poised and ready to move ahead... now.
Worldwide marketing of this Technology will have a multi-million-to-billion dollar profit potential. Profitability projections are based on a 58-62% profit margin computed against current unit costs of production and a 1<2% market penetration. Manufacturing costs should reduce significantly as market share and unit manufacturing increase, and as envisioned technological improvements, manufacturing techniques, and component designs evolve.
The Pitch:
Analogous to the medical devices of Star Trek and the healing light devices used by Doctors McCoy, Crusher and Phlox, the future of medical therapy, the Immunogenic Ig2000 Immune System Stimulator, is here today, and ready for use in today’s modern Doctor’s office.
Our company is proudly introducing its Ig2000 Therapeutic Medical Modality. It is a new and exciting scientific and technological breakthrough that will forever change the basics of current and emerging therapeutic medical delivery régimes.
The Ig2000 Technology is the first scientific advancement in medicine to bring photophysics and biotech together into one photo-immuno-biomodulative therapeutic modality.
The Ig Technology will enhance health care by moving the world’s health care delivery system protocols away from the standard and traditional surgical and pharmaceutical based treatments to that of a much safer non-invasive immuno-biomodulative alternative that can be used either as a stand-alone and/or adjunctive therapeutic.
Just as Professor Alexander Fleming’s discovery of antibiotics in 1928 has changed the course of medicine over the past 80+ years, the patented Immunogenic Technology of the Ig2000 will change the face of medicine, as we would have known it, into the far and distant future.
The Ig2000 modality is an advanced scientific and technological breakthrough in the field of Immune Modulation Therapy (IMT). It is a Revolutionary Disruptive Technology based on Quantum Physics, and Laser and Light Science. The Ig2000 is a “one of a kind” Medical Modality incorporating a novel and innovative biophotonic technology that has the unique ability to non-invasively stimulate and up-modulate the Immune System and the Immune Response in both animal and human subjects.
The Basics:
Much like sunlight and the process of Photosynthesis in plants, the beneficial effects generated by treatment with the Immunogenic Ig2000 Technology are also based upon the generation of atomic level molecular transformations brought about through the application of specific wavelength light on tissue and the molecular reactions which occur within that tissue when the applied light’s photons are absorbed. Specific molecular level biochemical transformations, transformations (acting like chemical switches) generated by this specific wavelength non-ionizing light, stimulate the Nitric Oxide Synthase (nNOS, iNOS and eNOS) process-chains affectively initiating the spontaneous generation and release of Nitric Oxide from the Nitric Oxide Synthase contained within the irradiated tissue. This newly released Nitric Oxide is then introduced both locally and systemically into the body.
The up-modulated and photo-stimulated production of the photo-initiated Nitric Oxide release then generates a therapeutic cascade of the immune response. This therapeutic cascade is the bio-mechanisma responsible for accelerated and sustained healing of injuries, ailments and disease.
Once the stimulation of the Immune System is initiated, the pro-active Immune Response, and the resulting therapeutic immune cascade then does the actual healing. This unique therapy technique allows for the application of the Ig Technology across numerous medical disciplines to successfully treat myriad immuno-responsive indications while displaying an efficacy and safety that has been heretofore unheard of, and do it without the negative side effects associated with drugs and/or surgery.
The Immunogenic Ig2000 Technology (applied athermically and non-invasively) has the inherent ability to treat many indications (like many indications of the eye, burns, or chronic infections) that were previously either untreatable or treatable only by drugs and/or surgery.
The Technology (deemed a Photoceutical™) is groundbreaking in inducing a healing response in the body through the photo-manipulation of molecules involved in/with the modulation of Nitric Oxide Synthase (NOS) and the generation of the cellular communicator, Nitric Oxide (NO). The patented Ig2000 is the first and only device that incorporates this advanced immuno-biostimulative and immuno-biomodulative technology.
The Ig’s Immunogenic Ig2000 Technology and its applied wavelength is FDA classified as Non-Significant Risk, Athermic, and Ocular Safe.
Clinical responses to Ig2000 therapies in the veterinary marketplace display consistent, repeatable and positive resolutions to injuries, ailments and disease, without negative side effects. Conditions treated that display significant improvements in treatment outcomes and recovery times over standard care include: upper respiratory conditions, tendon and ligament injuries, soft tissue traumas, wounds, burns and corneal ulcers. Successful Veterinary treatments administered with the device to date far exceed two-hundred and fifty thousand.
Proof of Concept Studies and Investigational Therapies conducted with human subjects have also demonstrated these same positive therapeutic outcomes, displaying resolutions that are also consistent, repeatable, and without negative side effects. Significant improvements in treatment outcomes and recovery times over standard medical treatment(s) are demonstrated in indications such as viral conditions, Herpes I and II, Herpes Zoster, non-healing diabetic ulcers, and pulmonary conditions including Pneumonia, Asthma and Emphysema. Two independent case studies involving CNS trauma have also demonstrated efficacy in neural regeneration/reinnervation. The Ig2000 technology further has the ability to mediate unmet medical needs such as intractable pain and quality of life issues such as symptoms related to cancer, i.e. inflammatory issues, appetite and sleep dysfunctions, and cancer related pain.
A distinct advantage of the Ig2000 technology is that, due to the base effect of the treatment affect on the immune system and the immune response, it can be applied efficaciously across multiple medical disciplines. The technology also has the advantage of being prescribable either as a standalone treatment modality or as an adjunctive therapy. The Immunogenic Ig2000 Technology also has a unique niche in both integrative (IM) and evidence-based medicine (EBM).
For answers to your questions or for more complete Information:
NDA, Executive Summary, Business Plan, Pro-Forma etc., please reply.